BioLife Solutions (BLFS) announced that as part of a larger round of financing it has purchased $2M of convertible notes in Pluristyx, a Seattle based developer of innovative induced pluripotent stem cell, or iSPC, based products for cell therapy developers. BioLife also entered into a separate agreement which provides a board observer seat, and certain rights related to any potential future acquisition of Pluristyx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS: